MX2023012030A - Combinacion que comprende un inhibidor especifico de histona desacetilasa 6 (hdac6) y al menos un inhibidor del punto de control del antigeno 4 del linfocito t citotoxico (ctla4). - Google Patents

Combinacion que comprende un inhibidor especifico de histona desacetilasa 6 (hdac6) y al menos un inhibidor del punto de control del antigeno 4 del linfocito t citotoxico (ctla4).

Info

Publication number
MX2023012030A
MX2023012030A MX2023012030A MX2023012030A MX2023012030A MX 2023012030 A MX2023012030 A MX 2023012030A MX 2023012030 A MX2023012030 A MX 2023012030A MX 2023012030 A MX2023012030 A MX 2023012030A MX 2023012030 A MX2023012030 A MX 2023012030A
Authority
MX
Mexico
Prior art keywords
inhibitor
combination
checkpoint inhibitor
ctla4 checkpoint
ctla4
Prior art date
Application number
MX2023012030A
Other languages
English (en)
Spanish (es)
Inventor
Pietro Samuele Pozzi
Gianluca Fossati
Flavio Leoni
Elisabetta Galbiati
Christian Steinkuhler
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of MX2023012030A publication Critical patent/MX2023012030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023012030A 2021-04-20 2022-04-19 Combinacion que comprende un inhibidor especifico de histona desacetilasa 6 (hdac6) y al menos un inhibidor del punto de control del antigeno 4 del linfocito t citotoxico (ctla4). MX2023012030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102021000009926A IT202100009926A1 (it) 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
PCT/EP2022/060287 WO2022223543A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor

Publications (1)

Publication Number Publication Date
MX2023012030A true MX2023012030A (es) 2023-10-24

Family

ID=76808052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012030A MX2023012030A (es) 2021-04-20 2022-04-19 Combinacion que comprende un inhibidor especifico de histona desacetilasa 6 (hdac6) y al menos un inhibidor del punto de control del antigeno 4 del linfocito t citotoxico (ctla4).

Country Status (17)

Country Link
US (1) US20240207228A1 (enExample)
EP (1) EP4326259A1 (enExample)
JP (1) JP7902198B2 (enExample)
KR (1) KR20230172001A (enExample)
CN (1) CN117177745A (enExample)
AR (1) AR125356A1 (enExample)
AU (1) AU2022262199A1 (enExample)
BR (1) BR112023021125A2 (enExample)
CA (1) CA3213275A1 (enExample)
CL (1) CL2023002894A1 (enExample)
CO (1) CO2023013780A2 (enExample)
IL (1) IL307649A (enExample)
IT (1) IT202100009926A1 (enExample)
MX (1) MX2023012030A (enExample)
PE (1) PE20242078A1 (enExample)
TW (1) TW202308609A (enExample)
WO (1) WO2022223543A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119424649A (zh) * 2024-02-29 2025-02-14 中山大学附属第一医院 假体周围感染治疗靶点及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190022203A1 (en) 2016-01-11 2019-01-24 Turnstone Limited Partnership Oncolytic virus and checkpoint inhibitor combination therapy
IT201700041723A1 (it) * 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6

Also Published As

Publication number Publication date
CN117177745A (zh) 2023-12-05
CL2023002894A1 (es) 2024-03-15
TW202308609A (zh) 2023-03-01
CO2023013780A2 (es) 2023-11-10
WO2022223543A1 (en) 2022-10-27
IL307649A (en) 2023-12-01
US20240207228A1 (en) 2024-06-27
IT202100009926A1 (it) 2022-10-20
BR112023021125A2 (pt) 2023-12-12
JP2024515100A (ja) 2024-04-04
PE20242078A1 (es) 2024-10-18
EP4326259A1 (en) 2024-02-28
AR125356A1 (es) 2023-07-12
CA3213275A1 (en) 2022-10-27
KR20230172001A (ko) 2023-12-21
AU2022262199A1 (en) 2023-09-21
JP7902198B2 (ja) 2026-08-07

Similar Documents

Publication Publication Date Title
ZA202204929B (en) Rimegepant for cgrp related disorders
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
MY200200A (en) Cd73 inhibitors
WO2010042489A3 (en) Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MY203645A (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2017010299A (es) Terapia de combinacion de inhibidores de la proteina de choque termico 90 (hsp90) e inhibidores de muerte programada 1(pd-1) para tratar cancer.
MX2021005740A (es) Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo.
MX2020001759A (es) Inhibidores de histona acetiltransferasa de la familia myst.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MX2014000204A (es) Metodo de administracion y tratamiento.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
ZA202103914B (en) Cxcr7 inhibitors for the treatment of cancer
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use